The prognostic importance of modifiable risk factors after heart transplantation

American Heart Journal

Volumn 158, Issue 3, 2009, Pages 431-436

  Arora, Satish ^a,b   Aukrust, Pål ^a,b   Andreassen, Arne ^a   Simonsen, Svein ^a   Gude, Einar ^a   Grov, Ingelin ^a   Geiran, Odd ^a,b   Fiane, Arnt ^a   Gullestad, Lars ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISOLONE; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIAC GRAFT REJECTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FOLLOW UP; HEART DEATH; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MORTALITY; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 68849099347     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.05.036     Document Type: Article

References (18)

1. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 26 (2007) 769-781
2. Valantine H.A. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4 (2004) 169-177
3. Gao S.Z., Schroeder J.S., Alderman E.L., et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation 80 5 Pt 2 (1989) III100-III105
4. Basile A., Bernazzali S., Diciolla F., et al. Risk factors for smoking abuse after heart transplantation. Transplant Proc 36 (2004) 641-642
5. Nagele H., Kalmar P., Rodiger W., et al. Smoking after heart transplantation: an underestimated hazard?. Eur J Cardiothorac Surg 12 (1997) 70-74
6. Clark A.L., Knosalla C., Birks E., et al. Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changes. Eur J Heart Fail 9 (2007) 839-844
7. Russo M.J., Chen J.M., Hong K.N., et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. Circulation 114 (2006) 2280-2287
8. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
9. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736-1740
10. Ingelsson E., Sullivan L.M., Fox C.S., et al. Burden and prognostic importance of subclinical cardiovascular disease in overweight and obese individuals. Circulation 116 (2007) 375-384
11. Wilson P.W., D'Agostino R.B., Sullivan L., et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162 (2002) 1867-1872
12. Ludwig D.S. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 287 (2002) 2414-2423
13. Rahmani M., Cruz R.P., Granville D.J., et al. Allograft vasculopathy versus atherosclerosis. Circ Res 99 (2006) 801-815
14. Mehra M.R. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 6 (2006) 1248-1256
15. Poggio E.D., Roddy M., Riley J., et al. Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. J Heart Lung Transplant 24 (2005) 1606-1613
16. Valantine H.A. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 76 (2003) 891-899
17. Vigano M., Tuzcu M., Benza R., et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 26 (2007) 584-592
18. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 107 (2003) 93-97